Clinical Trial Update: A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating luspatercept for anemia in patients with myeloproliferative neoplasm-associated myelofibrosis; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelofibrosis

Drugs mentioned

• Luspatercept (luspatercept)

Snippet

Sponsor: Celgene | Conditions: Primary Myelofibrosis, Anemia | Phase 2 | Status: COMPLETED | Results posted: 2023-08-24